UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1,2,3-Triazolo[1,5-a][1,4]- and 1,2,3-triazolo[1,5-a][1,5]benzodiazepine derivatives: synthesis and benzodiazepine receptor binding

Farmaco (Società chimica italiana : 1989), 1998-04, Vol.53 (4), p.305-311

1998

Volltextzugriff (PDF)

1,2,3-Triazolo[1,5-a]quinoxalines: synthesis and binding to benzodiazepine and adenosine receptors

European journal of medicinal chemistry, 1998-02, Vol.33 (2), p.113-122

1998

Volltextzugriff (PDF)

1,2,3-Triazolo[4,5-d]-1,2,4-triazolo[4,3-b]pyridazines

Journal of heterocyclic chemistry, 1997-01, Vol.34 (1), p.65-69

1997

Volltextzugriff (PDF)

1,2,3-Triazolo[4,5-d]pyridazines

Farmaco (Società chimica italiana : 1989), 1999-09, Vol.54 (9), p.615-623

1999

Volltextzugriff (PDF)

1,2,3-Triazolo[4,5-d]pyridazines: Part VI. New 1-substituted-4-amino derivatives and their affinity towards A 1 and A 2A adenosine receptors

Farmaco (Società chimica italiana : 1989), 1999, Vol.54 (9), p.615-623

1999

Volltextzugriff (PDF)

1,2,3-triazolo[4,5-d]pyridazines. Part VI. New 1-substituted-4-amino derivatives and their affinity towards A1 and A2A adenosine receptors

Farmaco (Società chimica italiana : 1989), 1999, Vol.54 (9), p.615-623

1999

Volltextzugriff (PDF)

1,2,3-Triazolo [4,5-d] pyridazines--V. Preparation and adenosine receptor binding of new 4-amino derivatives

Farmaco (Società chimica italiana : 1989), 1996-08, Vol.51 (8-9), p.601

1996

Volltextzugriff (PDF)

1,2,3-Triazolo[4,5-e]-1,2,4-triazolo[3,4-c]pyrimidines

Journal of heterocyclic chemistry, 1999-09, Vol.36 (5), p.1195-1198

1999

Volltextzugriff (PDF)

1,2-Dihydro-2-oxopyridine-3-carboxamides: The C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor

European journal of medicinal chemistry, 2014-03, Vol.74, p.524-532

2014

Volltextzugriff (PDF)

A 1.7 GHz Tuning Range LC-VCO with Varactors Array and Switched Cross-Coupled Core

2024 IEEE Computer Society Annual Symposium on VLSI (ISVLSI), 2024, p.699-703

2024

Volltextzugriff (PDF)

1,8-Naphthyridin-4-one derivatives as new ligands of A 2A adenosine receptors

Bioorganic & medicinal chemistry letters, 2005, Vol.15 (20), p.4604-4610

2005

Volltextzugriff (PDF)

1,8-Naphthyridin-4-one derivatives as new ligands of A sub(2A) adenosine receptors

Bioorganic & medicinal chemistry letters, 2005-10, Vol.15 (20), p.4604-4610

2005

Volltextzugriff (PDF)

1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors

Bioorganic & medicinal chemistry letters, 2005-10, Vol.15 (20), p.4604-4610

2005

Volltextzugriff (PDF)

1[alpha],25(OH)2-Vitamin D3 Increases Dysferlin Expression in vitro and in a Human Clinical Trial

Molecular therapy, 2012-10, Vol.20 (10), p.1988

2012

Volltextzugriff (PDF)

1 alpha ,25(OH) sub(2)-Vitamin D3 Increases Dysferlin Expression in vitro and in a Human Clinical Trial

Molecular therapy, 2012-10, Vol.20 (10), p.1988-1997

2012

Volltextzugriff (PDF)

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)

Journal of neurology, 2024-05, Vol.271 (5), p.2810-2823

2024

Volltextzugriff (PDF)

14th Italian Congress of Neuroepidemiology. Milan, Italy, November 21-22, 2014: Abstracts

Neuroepidemiology, 2015-01, Vol.43 (3-4), p.155-177

2015

Volltextzugriff (PDF)

15O Spatial transcriptomics analysis of Becker and Duchenne skeletal muscle to decipher histopathological alterations in dystrophinopathies

Neuromuscular disorders : NMD, 2024-10, Vol.43, p.104441, Article 104441.403

2024

Volltextzugriff (PDF)

O.16 Single cell RNA sequencing study of FAPS obtained from muscle samples of DMD patients reveals new pathogenic pathways of the muscle degeneration process

Neuromuscular disorders : NMD, 2022-10, Vol.32, p.S97

2022

Volltextzugriff (PDF)

1669P - Onco-i2b2 Project: A Bioinformatics Tool Integrating –Omics and Clinical Data to Support Translational Research

Annals of oncology, 2012-09, Vol.23, p.ix535-ix535

2012

Volltextzugriff (PDF)

167P SnRNAseq analysis of muscle samples of patients with SMA reveals novel pathogenic pathways and open avenues for new therapeutic strategies

Neuromuscular disorders : NMD, 2024-10, Vol.43, p.104441, Article 104441.602

2024

Volltextzugriff (PDF)

A 18F-FDG-PET Study on Brain Metabolic Correlates of King’s Staging System in ALS (1835)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

1st FSHD European Trial Network workshop:Working towards trial readiness across Europe

Neuromuscular disorders : NMD, 2021-09, Vol.31 (9), p.907-918

2021

Volltextzugriff (PDF)

1st International Workshop on Clinical trial readiness for sarcoglycanopathies 15–16 November 2016, Evry, France

Neuromuscular disorders : NMD, 2017-07, Vol.27 (7), p.683-692

2017

Volltextzugriff (PDF)

1α,25(OH)2-Vitamin D3 Increases Dysferlin Expression in vitro and in a Human Clinical Trial

Molecular therapy, 2012-10, Vol.20 (10), p.1988-1997

2012

Volltextzugriff (PDF)

1 – 25 von 2.849

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.215)
Mit Volltextzugriff
(2.249)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

1,2,3-Triazolo[1,5-a][1,4]- and 1,2,3-triazolo[1,5-a][1,5]benzodiazepine derivatives: synthesis and benzodiazepine receptor binding

1,2,3-Triazolo[1,5-a]quinoxalines: synthesis and binding to benzodiazepine and adenosine receptors

1,2,3-Triazolo[4,5-d]-1,2,4-triazolo[4,3-b]pyridazines

1,2,3-Triazolo[4,5-d]pyridazines

1,2,3-Triazolo[4,5-d]pyridazines: Part VI. New 1-substituted-4-amino derivatives and their affinity towards A 1 and A 2A adenosine receptors

1,2,3-triazolo[4,5-d]pyridazines. Part VI. New 1-substituted-4-amino derivatives and their affinity towards A1 and A2A adenosine receptors

1,2,3-Triazolo [4,5-d] pyridazines--V. Preparation and adenosine receptor binding of new 4-amino derivatives

1,2,3-Triazolo[4,5-e]-1,2,4-triazolo[3,4-c]pyrimidines

1,2-Dihydro-2-oxopyridine-3-carboxamides: The C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor

A 1.7 GHz Tuning Range LC-VCO with Varactors Array and Switched Cross-Coupled Core

1,8-Naphthyridin-4-one derivatives as new ligands of A 2A adenosine receptors

1,8-Naphthyridin-4-one derivatives as new ligands of A sub(2A) adenosine receptors

1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors

1[alpha],25(OH)2-Vitamin D3 Increases Dysferlin Expression in vitro and in a Human Clinical Trial

1 alpha ,25(OH) sub(2)-Vitamin D3 Increases Dysferlin Expression in vitro and in a Human Clinical Trial

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)

14th Italian Congress of Neuroepidemiology. Milan, Italy, November 21-22, 2014: Abstracts

15O Spatial transcriptomics analysis of Becker and Duchenne skeletal muscle to decipher histopathological alterations in dystrophinopathies

O.16 Single cell RNA sequencing study of FAPS obtained from muscle samples of DMD patients reveals new pathogenic pathways of the muscle degeneration process

1669P - Onco-i2b2 Project: A Bioinformatics Tool Integrating –Omics and Clinical Data to Support Translational Research

167P SnRNAseq analysis of muscle samples of patients with SMA reveals novel pathogenic pathways and open avenues for new therapeutic strategies

A 18F-FDG-PET Study on Brain Metabolic Correlates of King’s Staging System in ALS (1835)

1st FSHD European Trial Network workshop:Working towards trial readiness across Europe

1st International Workshop on Clinical trial readiness for sarcoglycanopathies 15–16 November 2016, Evry, France

1α,25(OH)2-Vitamin D3 Increases Dysferlin Expression in vitro and in a Human Clinical Trial

Suchergebnisse filtern